Health body opens market engagement on blood genotyping system
A health body seeks supplier input on a high-throughput blood group genotyping system, aiming to shape future services for donor and patient typing.
A health body seeks supplier input on a high-throughput blood group genotyping system, aiming to shape future services for donor and patient typing.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
NHS Blood and Transplant has opened early market engagement on a high-throughput blood group genotyping system, covering Human Erythrocyte Antigen and Human Leukocyte Antigen testing, signalling a push towards more automated, molecular approaches in donor and patient typing.
On 24th March 2026, NHS Blood and Transplant published a Prior Information Notice seeking suppliers for a high-throughput blood group genotyping system. The notice specifies a focus on Human Erythrocyte Antigen and Human Leukocyte Antigen genotyping solutions and invites expressions of interest for pre-procurement engagement meetings.
The organisation is therefore not yet buying equipment, but sounding out the market. By talking directly with potential suppliers before a formal tender, it can test what platforms exist, how they perform at scale and how different Human Erythrocyte Antigen and Human Leukocyte Antigen workflows might be combined in practice.
The emphasis on a “system” and on “high-throughput” suggests NHS Blood and Transplant is interested in more than individual assays or instruments. It points to an integrated approach, where equipment, reagents, software and support all contribute to a genotyping workflow capable of handling large numbers of donor and patient samples.
This engagement sits alongside a series of recent procurements that show transfusion services moving towards molecular and high-throughput techniques. In January 2026, AZIENDA USL DELLA ROMAGNA launched a contract for renting high-throughput technology for immunohematological typing of patients and donors in molecular biology, to be awarded on the basis of the best quality/price ratio.
A month later, in February 2026, Azienda Zero in Padova began a market survey on high-throughput diagnostic systems using luminex or microarray technology for blood group genotyping of donors. That notice, like the NHS Blood and Transplant engagement, looks beyond traditional serology and seeks to understand what modern, high-capacity platforms the market can offer.
Other buyers are combining molecular typing with more familiar immunohematology work. In October 2025, ASL 3 - PESCARA issued a tender for diagnostic systems and reagents for erythrocyte and platelet antigen typification in its Immunohematology Laboratory. In December 2025, Ypourgeio Ygeias went further, procuring consumables for molecular typing of red blood cell and platelet antigens, together with equipment on loan for blood banks and a blood centre.
Across several notices, the focus is on full workflows rather than standalone components. Centro Vasco de Transfusión y Tejidos Humanos, for example, published a contract in December 2025 for reagents to support immunohematological typing, including ABORh system typing, irregular antibody investigation and compatibility testing. Around the same time, Regionalne Centrum Krwiodawstwa i Krwiolecznictwa w Warszawie and Szpital Uniwersytecki w Krakowie sought not only reagents and microcards but also the lease of fully automated analysers and other diagnostic equipment.
Genotyping as a service model is not confined to human medicine. In January 2026, the Agriculture and Horticulture Development Board advertised genotyping services for a population of Holstein dairy cows with methane phenotypes across multiple UK dairy farms, covering tasks such as farm liaison, sample collection, DNA extraction and quality control. That notice shows buyers expecting providers to handle an end-to-end chain from field or clinic through to high-quality genetic data.
The Human Leukocyte Antigen element of the NHS Blood and Transplant engagement mirrors a strong pipeline of HLA-focused procurements. In December 2025, CHU Dupuytren Limoges went to market for reagents and consumables for medical biology related to histocompatibility, including lots for anti-HLA antibodies and HLA typing technologies.
Also in December 2025, AGEPS / APHP launched a contract for in vitro diagnostic medical devices and associated services for HLA histocompatibility studies across various hospitals. That procurement covers reagents, consumables and equipment for different HLA typing techniques and capacities, underlining how HLA work often involves multiple technologies deployed across a network of laboratories.
Several notices add a clear transplant dimension. In November 2025, the National Histocompatibility and Immunogenetics Service at Beaumont Hospital issued a framework agreement for the supply of single-antigen solid-phase HLA antibody screening kits used in solid organ transplant programmes. In March 2026, the Regional Blood Donation and Blood Treatment Centre in Poznan advertised the supply of reagents, materials and accessories for HLA system-related testing, including tests for antibodies, magnetic columns for lymphocyte isolation, DNA isolation kits and HLA typing kits with the necessary software and training.
Against this backdrop, NHS Blood and Transplant’s interest in Human Leukocyte Antigen genotyping solutions places its market engagement squarely within an evolving landscape for histocompatibility services. Buyers are not only ordering assays; they are specifying end-to-end HLA capabilities that link antibodies, DNA-based typing and specialised software, often supported by training and long-term supplier relationships.
The push towards high-throughput genotyping is only one strand of a broader modernisation of transfusion laboratories. Notices over the past year show parallel investment in pathogen screening and automated diagnostic platforms. In October 2025, Oblastní nemocnice Náchod sought laboratory NAT testing of samples from blood and blood component donors to ensure quality and safety in line with regulatory requirements. In March 2026, Institutul National de Transfuzie Sanguina Prof.Dr.C.T.Nicolau launched a tender for EIA screening reagents to detect anti-HTLV-I and anti-HTLV-II antibodies as part of a national transfusion safety programme.
Other buyers are coupling sophisticated testing with new instruments and service models. In January 2026, Universitätsmedizin Greifswald issued a contract notice for laboratory diagnostic equipment and reagents for molecular diagnostics in blood donation testing, including installation, commissioning and maintenance of analysis machines for detecting viral pathogens. Around the same time, ASL BA procured a fully automated diagnostic system using the ImmunoBlot technique for confirmation testing of HIV 1 and 2, HCV and Treponema pallidum for a hospital transfusion office, while the Blood Transfusion Center of the Valencian Community went to market for reagents and materials for analytical determinations covering blood group establishment, cell characterisation, flow cytometry and screening for infectious agents.
Alongside central laboratory upgrades, several notices highlight the supporting infrastructure and decentralised testing that sit around them. On 6th March 2026, the National Institutes of Health signalled its intention to award a contract to Manage Incorporated for IBM hardware and software support services for its Blood Bank Control System, noting that the supplier is the sole source capable of providing the necessary support. The notice underlines how legacy control systems remain critical to day-to-day blood bank operations, even as new analytical platforms are introduced.
Closer to the patient, health organisations are using market engagement to explore new testing models. In January 2026, the Business Services Organisation Procurement and Logistics Service began preliminary market engagement on a managed service contract for point of care testing, focusing on INR and handheld blood gas testing. In February 2026, the Department of Health & Social Care opened market engagement on venous-equivalent transdermal capillary blood sampling devices intended to enhance remote diagnostics in community and home settings, improve access for underserved populations and support earlier diagnosis of long-term conditions.
Taken together, these activities suggest that any future high-throughput blood group genotyping system for NHS Blood and Transplant will have to operate within a complex ecosystem of central laboratories, IT control systems and increasingly distributed diagnostic services. Suppliers entering the engagement discussions are likely to be asked not just about instruments, but about how their solutions interface with existing platforms and with emerging models of care.
The current notice from NHS Blood and Transplant is explicitly about pre-procurement engagement. Potential suppliers are being invited to express interest in meetings, rather than to submit formal bids. That gives both sides room to explore what “high-throughput” should mean in practice, how Human Erythrocyte Antigen and Human Leukocyte Antigen genotyping might be integrated, and what level of automation and support the health service will expect.
If a full procurement follows, it is likely to sit alongside the many recent tenders for immunohematology, HLA and pathogen screening systems, reagents and services issued by a wide range of health and laboratory bodies. For now, the key development to watch is how this early dialogue shapes the eventual specification – and whether it leads to a system that brings together the genotyping, software and service elements that are becoming common features of modern blood and transplant laboratory contracts.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.